Keith Dredge

4.6k citations

55 papers · 3.7k indexed · 1 hit paper · h-index 30

Impact in

Hematology top 0.5%
- Multiple Myeloma Research and Treatments
Cell Biology top 1%
- Proteoglycans and glycosaminoglycans research

Papers in

Hematology 14
- Multiple Myeloma Research and Treatments 13
Cell Biology 19
- Proteoglycans and glycosaminoglycans research 17

Co-authors: Angus Dalgleish J. Blake Bartlett Edward Hammond George W. Muller David Stirling J B Marriott Stephen Todryk Ian Bytheway
Journals: Molecular Cancer Therapeutics (4 papers)British Journal of Cancer (4 papers)Oncotarget (2 papers)Journal of Medicinal Chemistry (2 papers)Cancer Research (2 papers)
Partner nations: United States United Kingdom Australia

In The Last Decade

Keith Dredge

55 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

The evolution of thalidomide and its IMiD derivatives as anticancer agents 2004 · 632 citations

Peers

Countries citing papers authored by Keith Dredge

Since Specialization

Citations

This map shows the geographic impact of Keith Dredge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Dredge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Dredge more than expected).

Fields of papers citing papers by Keith Dredge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Dredge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Dredge. The network helps show where Keith Dredge may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Keith Dredge, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Keith Dredge Line = papers co-authored together Keith Dredge links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction Oncogene ·Upasana Ray, Prabhu Thirusangu, Ling Jin, Yinan Xiao, 文明黒羽, Julie Staub, Courtney L. Erskine, Keith Dredge, Edward Hammond, Matthew S. Block, Scott H. Kaufmann, Jamie N. Bakkum‐Gamez, Viji Shridhar	2023	7
2	Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors Journal for ImmunoTherapy of Cancer ·Charlotte Lemech, Keith Dredge, 野村雅之, Edward Hammond, Andrew D. Clouston, Nigel J. Waterhouse, Amanda C. Stanley, Lucie Leveque, Grace Chojnowski, Andrew Haydon, Nick Pavlakis, Matthew Burge, Michael P. Brown, David Goldstein	2023	26
3	A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitis Translational research ·T Mohan Reddy, Darren Pickering, Roland Ruscher, Yo‐Sep Yang, Linda Jones, 柳川雄大, 伊藤信彦, Stephanie Ryan, Kim Miles, Matthew A. Field, Keith Dredge, Norelle L. Daly, Paul Giacomin, Alex Loukas	2021	16
4	Heparanase Inhibition by Pixatimod (PG545): Basic Aspects and Future Perspectives Advances in experimental medicine and biology ·Edward Hammond, Keith Dredge	2020	12
5	Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors Journal for ImmunoTherapy of Cancer ·Edward Hammond, Nicole M. Haynes, Carleen Cullinane, Todd V. Brennan, 野村雅之, Paul Handley, Tomislav Karoli, MA Qi-hui, Liwen Lin, Yiping Yang, Keith Dredge	2018	35
6	A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours British Journal of Cancer ·Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin, 野村雅之, Paul Handley, Muzaffarova Zebiniso Hikmatullo qizi, Glynn Morrish, Yiping Yang, Michael P. Brown, Michael Millward	2018	73
7	Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and In Vivo Tumor Growth Molecular Cancer Therapeutics ·Naama Peltz Sinvani, Soumi Kundu, Aysha Saddiqa, Di Yu, Tommie Olofsson, Keith Dredge, Edward Hammond, Uri Barash, Israël Vlodavsky, Karin Forsberg‐Nilsson	2017	30
8	Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer Scientific Reports ·Debarshi Roy, Susmita Mondal, Ashwani Khurana, Nurhikma Nurhikma, Robert Hoffmann, Xiaoping He, Eleftheria Kalogera, Thomas Dierks, Edward Hammond, Keith Dredge, Viji Shridhar	2017	15
9	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer Molecular Cancer Therapeutics ·Katherine T. Ostapoff, Niranjan Awasthi, Bercin Kutluk Cenik, Stefan Hinz, Keith Dredge, Roderich E. Schwarz, Rolf A. Brekken	2013	62
10	Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth Journal of Medicinal Chemistry ·Ken D. Johnstone, Tomislav Karoli, Ligong Liu, Keith Dredge, Finn Reisegg., Cai Ping Li, Kat Davis, Edward Hammond, Ian Bytheway, Edmund Kostewicz, Francis C. K. Chiu, David M. Shackleford, Susan A. Charman, William N. Charman, Job Harenberg, Thomas J. Gonda, Vito Ferro	2010	64
11	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunology Immunotherapy ·Christine Galustian, B Meyer, Marie‐Christine Labarthe, Keith Dredge, О.В. Гагарина, Jake Y. Henry, Stephen Todryk, Roger Chen, George W. Muller, David Stirling, Peter Schäfer, J. Blake Bartlett, Angus Dalgleish	2008	324
12	VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29 Cancer Research ·Linghua Zhang, Ling Lu, Lei Wu, Keith Dredge, J. Blake Bartlett, Peter Schäfer, George W. Muller, Angus Dalgleish	2006	13
13	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvascular Research ·Keith Dredge, Henry Fuller Howden, Simon P. Robinson, Linghua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George W. Muller, Peter Schäfer, David Stirling, Angus Dalgleish, J. Blake Bartlett	2005	225
14	A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. PubMed ·J B Marriott, Ian Clarke, Anna Czajka, Keith Dredge, Kay Childs, Hon‐Wah Man, Peter Schäfer, T. L. Rokoske, George W. Muller, David Stirling, Angus Dalgleish	2003	45
15	Thalidomide analogs as emerging anti-cancer drugs Anti-Cancer Drugs ·Keith Dredge, Angus Dalgleish, J B Marriott	2003	34
16	Efficacy of intramammary treatment with procaine penicillin G vs. procaine penicillin G plus neomycin in bovine clinical mastitis caused by penicillin‐susceptible, gram‐positive bacteria – a double blind field study Journal of Veterinary Pharmacology and Therapeutics ·Suvi Taponen, Keith Dredge, Mehmet Akif TOPÇUOĞLU, C. Geisenhoff, Leena Suojala, Daakshini Patel, Healey Bruce, Satu Pyörälä	2003	29
17	Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity The Journal of Immunology ·Keith Dredge, J B Marriott, Stephen Todryk, George W. Muller, Roger Chen, David Stirling, Angus Dalgleish	2002	143
18	Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy Cancer Immunology Immunotherapy ·Keith Dredge, JinHee Jung, Stephen Todryk, Angus Dalgleish	2002	104
19	Recent developments in antiangiogenic therapy Expert Opinion on Biological Therapy ·Keith Dredge, Angus Dalgleish, J B Marriott	2002	15
20	Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression European Journal of Pharmacology ·Andrew Harkin, John Kelly, Mairéad G. McNamara, Thomas J. Connor, Keith Dredge, Anna Redmond, Brian E. Leonard	1999	79

About Keith Dredge

Keith Dredge is a scholar working on Hematology, Cell Biology, Immunology, Molecular Biology and Oncology, having authored 55 papers that have together received 3.7k indexed citations. Recurring topics across this work include Proteoglycans and glycosaminoglycans research (17 papers), Multiple Myeloma Research and Treatments (13 papers), Angiogenesis and VEGF in Cancer (13 papers), Fibroblast Growth Factor Research (10 papers), Glycosylation and Glycoproteins Research (9 papers), Protein Degradation and Inhibitors (8 papers), Immunotherapy and Immune Responses (7 papers) and Cancer, Hypoxia, and Metabolism (5 papers). The work is most often cited by research in Hematology (1.3k citations), Cell Biology (917 citations), Oncology (983 citations), Genetics (359 citations) and Molecular Biology (2.2k citations). Keith Dredge has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Angus Dalgleish, J. Blake Bartlett, Edward Hammond, George W. Muller, David Stirling, J B Marriott, Stephen Todryk, Ian Bytheway, Peter Schäfer and Vito Ferro. Their work appears in journals such as Molecular Cancer Therapeutics, British Journal of Cancer, Oncotarget, Journal of Medicinal Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact